Pacific Biosciences
PACB
174 hedge funds and large institutions have $1.47B invested in Pacific Biosciences in 2020 Q3 according to their latest regulatory filings, with 52 funds opening new positions, 62 increasing their positions, 41 reducing their positions, and 29 closing their positions.
740% more call options, than puts
Call options by funds: $6.31M | Put options by funds: $751K
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
291% more capital invested
Capital invested by funds: $375M → $1.47B (+$1.09B)
79% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 29
51% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 41
15% more funds holding
Funds holding: 151 → 174 (+23)
13.63% more ownership
Funds ownership: 70.5% → 84.13% (+14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$66.9M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$26M |
| 3 |
CC
Casdin Capital
New York
|
+$25.9M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
+$23.7M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$23.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$25.7M |
| 2 |
WIC
Water Island Capital
New York
|
-$22.4M |
| 3 |
KLCMU
Kite Lake Capital Management (UK)
London,
United Kingdom
|
-$19.2M |
| 4 |
GF
Gabelli Funds
Rye,
New York
|
-$11.9M |
| 5 |
GCM
Glenview Capital Management
New York
|
-$10.9M |
PACB Hedge Fund Activity: Q3 2020 in Review
174 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2020, worth a combined $1.47B — up 291% from $375M a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new PACB positions and 29 closed out — a net gain of 23 holders — while 62 added to existing stakes and 41 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $66.9M. The largest seller was Bellevue Group, cutting an estimated $25.7M.
- 174 institutional investors held Pacific Biosciences (PACB) as of Q3 2020, up from 151 in Q2 2020.
- Funds reported $1.47B of Pacific Biosciences stock for Q3 2020, up 291% quarter-over-quarter.
- 52 funds opened new Pacific Biosciences positions in Q3 2020 and 29 closed out, a net change of +23 holders.
- The largest Pacific Biosciences buyer in Q3 2020 was ARK Investment Management, an estimated $66.9M added.
- The largest Pacific Biosciences seller in Q3 2020 was Bellevue Group, an estimated $25.7M sold.
Based on aggregated 13F filings for Q3 2020.